Analyst Price Targets — CMPS
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 18, 2026 1:33 pm | — | RBC Capital | $22.00 | $8.78 | TheFly | Compass Pathways price target raised to $22 from $21 at RBC Capital |
| February 18, 2026 12:36 pm | Vikram Purohit | Morgan Stanley | $18.00 | $7.63 | TheFly | Compass Pathways price target raised to $18 from $11 at Morgan Stanley |
| February 18, 2026 12:03 pm | Sumant Kulkarni | Canaccord Genuity | $20.00 | $7.63 | TheFly | Compass Pathways price target raised to $20 from $15 at Canaccord |
| February 12, 2026 12:54 pm | Francois Brisebois | Compass Point | $15.00 | $6.31 | TheFly | Compass Pathways initiated with an Outperform at LifeSci Capital |
| January 23, 2026 7:25 pm | Leonid Timashev | RBC Capital | $21.00 | $7.17 | TheFly | Compass Pathways price target raised to $21 from $16 at RBC Capital |
| December 9, 2025 9:09 pm | — | Oppenheimer | $15.00 | $6.37 | TheFly | Compass Pathways upgraded to Outperform from Perform at Oppenheimer |
| July 22, 2024 4:24 pm | Leonid Timashev | RBC Capital | $23.00 | $7.43 | StreetInsider | RBC Capital Starts Compass Pathways (CMPS) at Outperform |
| June 5, 2024 9:16 am | Vikram Purohit | Morgan Stanley | $23.00 | $6.70 | StreetInsider | Compass Pathways (CMPS) PT Lowered to $23 at Morgan Stanley |
Latest News for CMPS
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the exercise of 35,059,448 warrants, which were issued on January 13, 2025, for proceeds of approximately $200 million. Upon exercise of these outstanding warrants, Compass Pathways is issuing 15,160,619 American…
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will attend the TD Cowen 46th Annual Healthcare Conference in Boston, MA, from March 2-4, 2026 and will participate in a fireside chat on March 3, 2026 at 10:30am ET. A live audio…
Treatment-Resistant Depression (TRD) stands as one of the most stubborn and costly challenges in modern healthcare. For the millions of patients who have cycled through multiple antidepressants without relief, the treatment landscape has long been a graveyard of failed promises.
Cathie Wood's ARK Invest added to Figma (FIG) and trimmed DraftKings (DKNG) on Feb. 19, as part of a broader portfolio reshuffle.ARK funds bought about $24 mill
LONDON & NEW YORK--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the pricing of its public offering of 17,500,000 American Depositary Shares (“ADSs”) at a public offering price of $8.00 per ADS, each representing one ordinary share, and in lieu of ADSs, to certain institutional investors, pre-funded…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CMPS.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.